| Similar Articles |
|---|
 |
The Motley Fool
January 10, 2012
Sean Williams |
Could This Stock Nearly Double 2 Years In a Row? Up 96% in 2011, there's a decent chance at a Jazz Pharmaceuticals repeat in 2012.   |
The Motley Fool
August 18, 2010
Brian Orelli |
No Pain Here as Jazz Shares Rocket Investors are all jazzed up about Jazz Pharmaceuticals |
The Motley Fool
August 23, 2010
Brian Orelli |
No Way to Jazz Up This Result Jazz Pharmaceuticals investors went from ecstatic to devastated in less than a week. |
The Motley Fool
October 11, 2010
Brian Orelli |
FDA Rejection, but Still Jazzed Up Sometimes, biotechs are like that. |
The Motley Fool
April 27, 2011
Brian D. Pacampara |
Jazz Pharmaceuticals Shares Plunged then Recovered: What You Need to Know Shares of drug maker Jazz Pharmaceuticals suddenly plummeted 30% this morning only to quickly recover the majority of that loss. |
The Motley Fool
March 30, 2011
Sean Williams |
China Clamps Down on Drug Manufacturers These drug manufacturers could be feeling a pinch from new Chinese price caps. |
The Motley Fool
October 18, 2005
Stephen D. Simpson |
More Good News From Novartis This Swiss drug giant continues to post steady growth. Investors, take note. |
The Motley Fool
May 3, 2011
Brian Orelli |
Teva's Branded-Drug Binge For a company that's a generic-drug maker, Teva Pharmaceuticals sure does like its branded drugs. Despite the warts the company is ponying up $6.2 billion to buy Cephalon. |
The Motley Fool
November 13, 2009
Rich Duprey |
5 Stocks That Laugh at Wall Street These companies' earnings handily beat analyst forecasts: General Steel... Jazz Pharmaceuticals... MGM Mirage... Stillwater Mining... Penn West Energy... |
The Motley Fool
June 14, 2007
Ryan Fuhrmann |
Dueling Fools: GlaxoSmithKline Bear Rebuttal There are better opportunities to use short-term pain and establish positions in pharmaceuticals with better long-term potential. |
The Motley Fool
August 28, 2007
Brian Orelli |
Teva Gets a Two-For Even for a maker of generic drugs, getting two FDA drug approvals in as many business days is a feat not often seen. Teva Pharmaceuticals managed to do it, though. Investors, take note. |
The Motley Fool
April 13, 2010
Brian Orelli |
Teva Gets Less Generic The generic-drug maker makes a major push into branded-drug development. |
The Motley Fool
September 3, 2011
Seth Jayson |
A Hidden Reason Why the Future Looks Bright for Jazz Pharmaceuticals Jazz Pharmaceuticals seems to be handling inventory well enough, but the individual segments don't provide a clear signal. |
The Motley Fool
January 13, 2004
Jeff Hwang |
Eon Labs' Potent Potential The generic drug maker's fourth-quarter estimates spiked higher. |
The Motley Fool
December 28, 2007
Brian Orelli |
The Biggest Health-Care IPOs of 2007 Let's take a look at four of the most intriguing health care IPOs from 2007. |
Chemistry World
January 27, 2014
Jennifer Newton |
Jazz spending spree has ups and downs Jazz Pharmaceuticals has agreed with Aerial Bio Pharma to acquire the rights to ADX-N05, a drug designed to treat narcolepsy. |
The Motley Fool
August 23, 2004
Ben McClure |
Rethinking Big Pharma Risk is knocking Big Pharma stocks down. They won't be getting up anytime soon. Competition, soaring R&D costs, shifting business models, and political meddling combine to make drug stocks a riskier place to invest. |
The Motley Fool
March 25, 2011
Selena Maranjian |
Make Money in Pharmaceuticals the Easy Way There's no need to guess which pharmaceutical company will perform best with the SPDR S&P Pharmaceuticals ETF. |
The Motley Fool
November 5, 2004
Roger Nusbaum |
The Tale of Teva Generic drug companies like Teva may offer a smart way to own health care. However, the company's good fortune hit a bump when rival Andrx got pummeled with a bad earnings announcement, and Teva traded down in sympathy. |
The Motley Fool
August 2, 2004
Charly Travers |
What's a Drug Worth? The value of small biotech companies is in their investigational drug programs. |
The Motley Fool
April 21, 2004
Ben McClure |
Discount Pharmacy With prices beaten down across the pharmaceuticals industry and the quarterly reporting season here, do any investment opportunities pop up? |
The Motley Fool
April 11, 2011
Jim Mueller |
A Missed Opportunity Cephalon showed up on my screen as a potential buy, but others liked it, too. |
The Motley Fool
November 22, 2005
Brian Gorman |
Saying No to Drugs Britain's policy of restricting drug access based on cost-benefit analyses should be on the radar screen of pharmaceutical investors. |
The Motley Fool
November 9, 2007
Brian Lawler |
Cephalon Wheels and Deals Sales and net income fall in the third quarter, but increased guidance sends shares of the drugmaker higher. |
The Motley Fool
June 28, 2011
Eric Bleeker |
Where Is Teva Pharmaceuticals Finding Growth? Teva should see its sales continue to climb, especially in already booming international markets. |
Chemistry World
May 15, 2009
Katrina Megget |
Tripping over red tape The UK may be moving a step closer to allowing the use of a cannabis-based drug to treat the symptoms of multiple sclerosis |
The Motley Fool
August 27, 2010
Rick Aristotle Munarriz |
This Week's 5 Dumbest Stock Moves Let's take a look at five dumb financial events this week that may make your head spin. |
AskMen.com
Ryan McKee |
How To: Keep Up In A Jazz Conversation If you can hold your own and keep up in a jazz conversation, women will think you're deep, with art appreciation coursing through your veins. |
Smithsonian
November 2005
Tom Piazza |
35 Who Made a Difference: Wynton Marsalis In Katrina's aftermath, the trumpeter has rallied support for his native New Orleans. |
